iX Biopharma Ltd. (SG:42C)
SGX:42C
Want to see SG:42C full AI Analyst Report?
Top Page
iX Biopharma Ltd.
(SGX:42C)
Select Model
Select Model
Rating:45Neutral
Price Target:
S$0.35
▼(-13.50% Downside)
Action:Reiterated
Date:04/18/26
The score is primarily weighed down by weak financial performance, including heavy leverage, persistent losses, and negative operating/free cash flow. Technicals provide partial support due to strong upside momentum and a positive MACD, but overbought RSI/Stoch increase short-term downside risk. Valuation contributes limited support given the provided P/E (0.000) and no dividend yield.
Positive Factors
Proprietary oral-film platform
Owning the WaferiX oral-film platform creates a durable technological moat: it supports differentiated product formulations, enables licensing and partner programs, and reduces commoditization risk. Such platform IP can generate recurring milestone/royalty income over multiple years.
Negative Factors
High financial leverage
Very high debt-to-equity (16.17) signals structural financing risk: elevated interest and principal obligations constrain strategic investments, increase refinancing vulnerability, and can force prioritization of debt service over R&D or commercial expansion during adverse cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oral-film platform
Owning the WaferiX oral-film platform creates a durable technological moat: it supports differentiated product formulations, enables licensing and partner programs, and reduces commoditization risk. Such platform IP can generate recurring milestone/royalty income over multiple years.
Read all positive factors
iX Biopharma Ltd. (42C) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$364.63M
Dividend YieldN/A
Average Volume (3M)15.11M
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth3.27%
EPS Growth43.59%
CountrySG
Employees35
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,056,907,200
10 Day Avg. Volume11,332,920
30 Day Avg. Volume15,113,843
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)38.32
Price to Sales (P/S)1.80
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
S$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iX Biopharma Ltd. Business Overview & Revenue Model
Company Description
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and...
How the Company Makes Money
iX Biopharma makes money primarily through (1) sales of pharmaceutical products and (2) monetizing its drug-delivery platform and manufacturing capabilities. Product revenue can come from commercial sales of iX Biopharma-branded or iX-developed me...
iX Biopharma Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.77M | 5.96M | 5.91M | 14.39M | 1.75M |
| Gross Profit | 2.04M | 1.05M | 2.32M | 12.29M | -382.00K |
| EBITDA | -8.96M | -8.68M | -8.51M | -2.84M | -10.79M |
| Net Income | -10.14M | -10.79M | -9.62M | -4.60M | -8.23M |
Balance Sheet | |||||
| Total Assets | 11.28M | 14.62M | 24.93M | 28.52M | 18.86M |
| Cash, Cash Equivalents and Short-Term Investments | 866.00K | 1.77M | 6.52M | 13.49M | 6.21M |
| Total Debt | 5.90M | 5.20M | 4.34M | 4.41M | 4.24M |
| Total Liabilities | 10.92M | 10.28M | 9.08M | 8.77M | 7.15M |
| Stockholders Equity | 365.00K | 4.34M | 15.85M | 19.74M | 11.71M |
Cash Flow | |||||
| Free Cash Flow | -3.96M | -6.84M | -8.36M | 2.92M | -8.90M |
| Operating Cash Flow | -3.76M | -6.55M | -7.66M | 3.12M | -8.35M |
| Investing Cash Flow | -201.00K | 1.06M | -695.00K | -5.62M | -507.00K |
| Financing Cash Flow | 3.12M | 724.00K | 1.42M | 9.79M | 10.02M |
iX Biopharma Ltd. Technical Analysis
Neutral
0.40
Price Trends
0.30
Positive
0.24
Positive
0.16
Positive
Market Momentum
0.02
Positive
49.51
Neutral
9.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42C, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.30, and above the 200-day MA of 0.16, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 9.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:42C.
iX Biopharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | S$38.81M | -10.60 | -8.35% | ― | 2.83% | -0.71% | |
45 Neutral | S$364.63M | ― | -450.81% | ― | 3.27% | 43.59% | |
43 Neutral | S$54.19M | -1.83 | -47.62% | ― | -1.27% | 16.67% | |
42 Neutral | S$78.00M | -6.84 | -300.34% | ― | ― | ― |
* Healthcare Sector Average
SG:42C
iX Biopharma Ltd.
0.35
0.33
1929.41%
SG:P8A
Cordlife Group
0.15
-0.12
-43.70%
SG:1J5
Hyphens Pharma International Ltd.
0.32
0.04
15.52%
SG:546
Medtecs International Corporation Ltd.
0.13
>-0.01
-2.22%
SG:8YY
Biolidics Ltd.
0.05
0.02
87.50%
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.04
<0.01
10.00%
iX Biopharma Ltd. Corporate Events
iX Biopharma Restructures Consumer Arm and Advances U.S. Joint Venture Plans
May 11, 2026
iX Biopharma is consolidating its Australian and Hong Kong consumer assets, a portfolio of about 40 WaferiX-based formulations, and a planned direct-to-consumer telehealth platform into a new wholly owned holding company, Ligo Pharma Pte. Ltd. Lig...
iX Biopharma Grants 9.4 Million Shares Under Performance Plan
May 8, 2026
iX Biopharma has granted 9,400,892 ordinary shares under its iX Performance Share Plan to employees, excluding the chairman and CEO, as part of an equity-based incentive program. The awards, priced at S$0.41 per share based on the market close on ...
iX Biopharma Clarifies Time-Based Vesting of Performance Shares Ahead of EGM
May 2, 2026
iX Biopharma has addressed a shareholder query ahead of its extraordinary general meeting on 8 May 2026, clarifying the terms of performance shares granted to executive Mr. Eddy Lee Yip Hang. The company referred investors to its earlier sharehold...
iX Biopharma Wins Conditional SGX Nod for New Share Placement
Apr 30, 2026
iX Biopharma has received a listing and quotation notice from the Singapore Exchange for 1,349,434 new ordinary shares to be issued under proposed placements to Anson Properties Pte. Ltd. and certain directors. The approval is conditional on share...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.